September 15, 2026 · Phase 2 readout
NVSEF Phase 2 readout: a positive outcome, +5.4%
On September 15, 2026, TOUR006 - 20 MG — NOVARTIS AG (Thyroid Eye Disease) reached its Phase 2 readout. The result was a positive outcome, and the stock moved +5.4% in the window around the event. It had already run -12.7% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$134.75
1d before
$142.06
Event day
$142.06
1d after
$142.06
5d after
Pre-catalyst setup
-12.7%
30-day run-up
9078%
30-day volatility
0.1×
volume spike